Published in Lab Invest on March 27, 2017
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 17.54
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2010) 11.16
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature (1989) 9.29
An essential role for ectodomain shedding in mammalian development. Science (1998) 9.14
Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med (1998) 8.56
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80
Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol (1999) 7.66
CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature (2006) 7.17
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
T-cell function and migration. Two sides of the same coin. N Engl J Med (2000) 6.47
CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol (2008) 5.35
P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues. Nature (1997) 5.17
An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw18-dependent mechanism. J Immunol (1986) 5.14
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science (2010) 4.56
TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell (2005) 4.46
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys (2004) 4.29
Mechanism of lymphocyte-mediated cytotoxicity. Annu Rev Immunol (1985) 4.19
Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol (2008) 4.17
The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical features. J Infect Dis (1985) 4.08
DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat Immunol (2007) 3.96
Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene (2009) 3.90
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res (2009) 3.83
CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol (2011) 3.73
Regulatory T cells: how do they suppress immune responses? Int Immunol (2009) 3.58
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature (2016) 3.54
CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med (2001) 3.51
Enhancement of LFA-1-mediated cell adhesion by triggering through CD2 or CD3 on T lymphocytes. Nature (1989) 3.36
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med (2008) 3.35
Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol (1997) 3.24
Understanding the generation and function of memory T cell subsets. Curr Opin Immunol (2005) 3.22
Rationally engineered Cas9 nucleases with improved specificity. Science (2015) 3.14
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med (2005) 3.01
Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med (2008) 2.97
Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer (2010) 2.93
Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol (2013) 2.92
A unique phenotype of skin-associated lymphocytes in humans. Preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol (1990) 2.84
The ins and outs of leukocyte integrin signaling. Annu Rev Immunol (2009) 2.76
Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol (2014) 2.71
Current concepts in the diagnosis and management of cytokine release syndrome. Blood (2014) 2.63
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med (2008) 2.60
Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature (1997) 2.56
L-selectin-negative CCR7- effector and memory CD8+ T cells enter reactive lymph nodes and kill dendritic cells. Nat Immunol (2007) 2.51
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A (2012) 2.50
Deficiency of a granulocyte-membrane glycoprotein (gp150) in a boy with recurrent bacterial infections. N Engl J Med (1982) 2.47
An inherited abnormality of neutrophil adhesion. Its genetic transmission and its association with a missing protein. N Engl J Med (1980) 2.32
Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res (2011) 2.24
Lymphocyte trafficking across high endothelial venules: dogmas and enigmas. Nat Rev Immunol (2004) 2.24
HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol (2012) 2.18
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell (2016) 2.15
Bimolecular complex between rolling and firm adhesion receptors required for cell arrest; CD44 association with VLA-4 in T cell extravasation. Immunity (2004) 2.10
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09
Preferential migration of effector CD8+ T cells into the interstitium of the normal lung. J Clin Invest (2005) 2.07
Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nat Immunol (2006) 2.05
The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol (2000) 2.03
Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology (2009) 2.01
Effects of tumor necrosis factor, lipopolysaccharide, and IL-4 on the expression of vascular cell adhesion molecule-1 in vivo. Correlation with CD3+ T cell infiltration. J Immunol (1992) 1.96
Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer (2014) 1.95
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (2016) 1.95
Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med (2009) 1.94
Transendothelial migration of lymphocytes mediated by intraendothelial vesicle stores rather than by extracellular chemokine depots. Nat Immunol (2011) 1.93
T cell exclusion, immune privilege, and the tumor microenvironment. Science (2015) 1.88
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res (2008) 1.85
Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets (2007) 1.82
12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep (2012) 1.81
Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med (1992) 1.81
CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood (2002) 1.81
Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med (2009) 1.78
Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res (2008) 1.77
Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J (2006) 1.76
T cell trafficking in allergic asthma: the ins and outs. Annu Rev Immunol (2008) 1.76
Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol (2012) 1.71
IL-2: the first effective immunotherapy for human cancer. J Immunol (2014) 1.71
Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med (1999) 1.70
The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Med (2015) 1.69
Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med (2008) 1.67
VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res (2011) 1.62
Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J (2003) 1.61
Identification of surface proteins mediating adherence of CD11/CD18-deficient lymphoblastoid cells to cultured human endothelium. J Clin Invest (1990) 1.61
Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res (2011) 1.61
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene (2008) 1.59
Vascular E-selectin expression correlates with CD8 lymphocyte infiltration and improved outcome in Merkel cell carcinoma. J Invest Dermatol (2013) 1.58
T-cell recruitment to the intestinal mucosa. Trends Immunol (2008) 1.57
Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest (2012) 1.55
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med (2014) 1.55
Human tumor antigens recognized by T cells. Curr Opin Immunol (1996) 1.54
CTLA-4 up-regulation of lymphocyte function-associated antigen 1 adhesion and clustering as an alternate basis for coreceptor function. Proc Natl Acad Sci U S A (2005) 1.51
Integrin function in T-cell homing to lymphoid and nonlymphoid sites: getting there and staying there. Crit Rev Immunol (2009) 1.49
PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med (2013) 1.48
CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med (2010) 1.48
The lymphocyte homing receptors: gatekeepers of the multistep paradigm. Curr Opin Hematol (2005) 1.48
T-cell receptor signaling to integrins. Immunol Rev (2007) 1.47